The past year may have been successful for a large number of shareholders. But there were also outliers: are the losers of yesterday the winners of tomorrow?
• The largest losers of the S&P 500 in 2024 with price losses between 49 and 64 percent
• Analyst assessments for the flop shares sometimes show potential for relaxation
• Challenges and uncertainties remain
The wide US index S&P 500, including dividends, increased by around 25 percent last year and thus seamlessly linked its strong development from the previous year: As early as 2023, the stock market barometer had gained more than 26 percent of value. The market was once again driven by the strong performance of techtities, but also the communication services and the consumer goods sector developed strongly. But there were-the outliers down, also in the top performer industry.
The flops of the S&P 500 2024
Investors from Walgreens had to accept the biggest discount, followed by Intel shareholders. But Moderna, Celanese and Estée Lauder also caused significant losses in the investor deposits in 2024. In the middle of a strong bull market, each of these titles in the broad market went down vigorously – between 49 and 64 percent.
Does this tendency continue in 2025? Analysts evaluate the flop acts of the S&P 500 in the new year quite differently.
Estèe Lauder
The Estée Lauder share has lost 49 percent in 2024. However, the American cosmetics manufacturer has not been under pressure on the stock exchange since last year-since the Corona period, the share certificate has been continuously down-from its all-time high, which was marked in January 2022 at $ 356.68 , the title is now worlds away. Finally, investors on the stock exchange had to put $ 72.18 on the table for an Estée Lauder share (as of February 18, 2025).
Too little, apparently analysts believe: The average price target for the Estée Lauder share is 77.25 US dollars on Tipranks, so that around 7.04 percent would still be air for possible recovery. Course heights like in 2022, however, probably sees no expert, especially since the ratings are also mixed. Of the 22 ratings, only five run to “buy”, 16 analysts award a “hold” evaluation, one even advises to turn off the share certificate.
The hope for a trend reversal for business – especially on the battered Asian market – should not justify the manageable price target. Investors are particularly concerned about the restructuring costs and the increasing degree of debt of the company. S&P Global Ratings also sees this as one of Estée Lauder’s biggest problems – accordingly, the experts have recently downgraded their rating for the company from “A” to “A-“.
Celanese
The Celanese share was 55 percent down last year. The share certificate has had volatile trading years, since 2020 the title has been commuting between around $ 75 and more than $ 174. Since autumn 2024, however, the bears have taken over the rudder because missed profit and sales forecasts had shocked investors in the third quarter. The chemical company led an demand for demand as the reason for the weak business development and admitted that it should continue in the subsequent quarter. The fact that cost reduction measures were announced in this context, which also included a massive reduction in the dividend, increased the pressure on the proportion certificate.
The Celanese share in 2025 should not endure quite as bad as 2024-at least if you may believe analysts: the experts award an average 12-month course goal of $ 78.69 and thus expect a recovery of the Subject by around 13 percent (as of February 18, 2025). But conviction can hardly be seen on the expert side – of 13 ratings there are only four on “buy”. There are two sales recommendations for seven “hold” ratings.
Accordingly, the possible course of the course should not be thanks to the hope of a turnaround. The fact that the company is now exposed to investigations due to securities fraud should also not serve to restore investor trust.
Moderna
The Moderna Biotech Group lost around 58 percent last year. The high flight from the Corona years is finally over, and the majority of disillusionment has now become prevailed on the investor side. The Moderna share still cost around $ 450 in 2021-with a current price level of $ 35.75, the share certificate is only worth a fraction of it (as of February 18, 2025).
It is thanks to new bad news that the share certificate has not been getting up to date even in the current year. After the Corona period, the vaccine business is anything but satisfactory, and the demand for covid vaccines has broken massively. The second approved Moderna vaccine, an RSV vaccin, should have been a hope of hope-but here too, demand is less than expected, in Germany it was not even enough for a recommendation by the constant vaccination commission.
The fact that the biotech group has severely reduced its sales forecast in this business situation was disappointed on the market. At Moderna, cost reduction measures are now a priority, which does not suggest that the business will be recovered soon.
Analysts apparently consider the crash of the Moderna share to be exaggerated. With an average price target of $ 46.43, you trust the share of the share of around 30 percent. Nevertheless: Bullen are only a few among the Moderna analysts: Out of 17 ratings are only two on “buy”, the majority of experts, eleven in number, at least advise you to keep the stock, while four analysts “sell” rating have forgiven.
Intel
In the middle of the chip and AI euphoria, which had driven shares from Nvidia in 2024 to new heights, Intel had to accept a price discount of 60 percent in the S&P 500 2024. Even if the downward trend at Intel accelerated significantly last year: the semiconductor manufacturer has not been satisfactory on the stock exchange for some time.
The US company was once a market leader in the semiconductor industry, now it is cut off, which is also due to the fact that the trend topic of artificial intelligence has more or less overslept. The fact that a direct competitor even in the traditionally dominated market for end customers has passed the US traditional group in the traditional market for end customers is consequently consequently a number of entrepreneurial wrong decisions. The success -spoiled company has also massively harmed the fact that large -scale Apple is now relating to its own chips.
Intel struggled better than feared in the recent fourth quarter, but there were significant declines in the previous year in terms of sales and the result. And the business is likely to remain difficult, Intel sweared in his shareholder base. The sales forecast for the current quarter was worse than hoped for.
This means nothing good for the battered Intel share. The average price target of analysts with $ 22.67 is around 17 percent below the current price level, but the massive price losses of the past year would not even be compensated for (as of February 18, 2025). 33 ratings were awarded for the Intel share according to Tipranks: 27 of which run on “hold”. Only one analyst has given a purchase recommendation, five advises to throw the share certificate out of the depots.
Only a few experts think that Intel can tear the helm alone. Instead, investors and observers rely on a possible takeover of the traditional group. The course should not be equally conducive that a possible prospect has recently been jumped off with Qualcomm.
Walgreens
Walgreens Boots Alliance is the inglorious leader of the flop shares in the S&P 500 index for 2024. A whopping 64 percent low Castle at the end of the year. The year had already started weakly for the largest US pharmacy chain: In February 2024, the Walgreens share flew from the renowned Dow Jones Index-the company was replaced by the Commercial Giant Amazon. Not only the strength of the internet giant, but also a share split at Walgreens, which had dropped the weighting of the share in the Dow, was responsible for this decision.
But the capital measure alone was not the reason for the crash of Walgreens, and retailer has had problems for years. The company had exaggerated opiod lawsuits, in China value reports had led to a loss of billions at the company level. In 2015, the IPO of Walgreens was still $ 100 billion-the company on the stock exchange is now still worth $ 8.38 billion (as of February 10, 2025).
Cost reduction measures are also the requirement of the hour at Walgreens: 1,200 shops are to be closed in the next three years, and investors will not receive a dividend for the time being. So one wants to work towards a renovation that “is based on a sustainable economic model”. A takeover is always in conversation – recently a financial investor had shown interest.
For analysts, apparently no reason to have too much trust in the Walgreens share. The average twelve-month course goal at $ 11.63 is $ 5.30 percent above the current price level (as of February 18, 2025), in view of the massive dropout last year, this would only be a drop in the hot Stone. Ten analysts evaluate the share – seven of them “hold”. A single purchase recommendation is compared to two sale recommendations.
Editor finance.net
This text serves exclusively for information purposes and does not represent an investment recommendation. Finance.net GmbH excludes any regress entitlements.